Kempen & Co is pleased to announce that it acted as Joint Bookrunner in Q-linea’s SEK 301m Capital Increase
Q-linea is a diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. The company has signed a global partnership (excl. Sweden) with Thermo Fisher for the commercialisation of ASTar®. ASTar® recently achieved CE-IVD approval allowing Q-linea and Thermo Fisher to start commercialisation in Europe. In addition, the Q-linea recently initiated a 510(k) US clinical study for ASTar® with the goal of submitting a 510(k) application to the FDA during 2021.
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: